291: The plight of the VC, Gilead's latest setback, & more M&A
We discuss how biotech's downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. We also take a look at Gilead Sciences' struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm.\nSubscribe to our biotech newsletter, The Readout.